Clinical Trials Directory

Trials / Completed

CompletedNCT02316522

Epigenetic Contribution to the Pathogenesis of Diabetic Nephropathy in Qatari Population

Status
Completed
Phase
Study type
Observational
Enrollment
158 (actual)
Sponsor
Weill Medical College of Cornell University · Academic / Other
Sex
All
Age
18 Years – 90 Years
Healthy volunteers
Accepted

Summary

The main objective is to study the epigenetic contribution to the pathophysiology of diabetic nephropathy in Qatari population.

Detailed description

Diabetic nephropathy (DN) is a common vascular complication of Type 2 diabetes (T2D) that is associated with increased mortality and poor quality of life.In industrialized countries, DN ranges first among other etiologies of end-stage renal disease (ESRD).Diabetes in Qatar is a serious health issue for the Qatari population since approximately 1/5 of the population has T2D, which is 2-3 times higher than the world average. As observed in other Gulf cooperation council (GCC) countries, obesity and sedentary lifestyle are cornerstones in the development of T2D. Additionally, consanguineous marriages in Qatar contribute to this high prevalence. As a consequence, DN has an enormous burden in terms of management, treatment and especially in renal replacement therapy (RRT) in ESRD in Qatari Population.DN is a glomerular disease defined by increased urinary albumin excretion (UAE), hypertension and decline in the glomerular filtration rate (GFR), all induced by chronic hyperglycemia. However, there are other contributing factors such as genetic predisposition, systemic and intra-renal hemodynamic disturbances, all leading to glomerulosclerosis. All of the known pathways do not explain the complex pathophysiology behind DN. Even different variants of genes described in major GWAS studies have little impact in terms of risk prevention or prognosis of DN. Over the last decade, epigenetics have initiated a new era in Genetic Medicine capable of giving a different approach to human disease.

Conditions

Timeline

Start date
2014-10-23
Primary completion
2018-04-09
Completion
2018-04-09
First posted
2014-12-15
Last updated
2022-05-02

Locations

1 site across 1 country: Qatar

Source: ClinicalTrials.gov record NCT02316522. Inclusion in this directory is not an endorsement.

Epigenetic Contribution to the Pathogenesis of Diabetic Nephropathy in Qatari Population (NCT02316522) · Clinical Trials Directory